Clearstead Advisors’s United Therapeutics UTHR Stock Holding History

Clearstead Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.3K	Sell	43 -505	-92%	-$284K	﹤0.01%	1753
2026 Q1	$325K	Sell	548 -583	-52%	-$290K	﹤0.01%	833
2025 Q4	$551K	Buy	1,131 +851	+304%	+$396K	0.01%	628
2025 Q3	$117K	Buy	280 +23	+9%	+$7.74K	﹤0.01%	1004
2025 Q2	$73.8K	Buy	257 +158	+160%	+$47.2K	﹤0.01%	1161
2025 Q1	$30.5K	Buy	+99	New	+$33.9K	﹤0.01%	1296

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Clearstead Advisors's UTHR Position: Q2 2026 in Review

Clearstead Advisors reduced its United Therapeutics (UTHR) stake by 92% in Q2 2026, selling an estimated $284K and leaving 43 shares worth $23.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1753.

Clearstead Advisors first reported a position in UTHR in Q1 2025 and has held it in 6 quarters since. The position peaked at $551K in Q4 2025. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Clearstead Advisors held 43 shares of United Therapeutics worth $23.3K as of Q2 2026.
Clearstead Advisors sold 505 United Therapeutics shares in Q2 2026, an estimated $284K.
United Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1753 holding.
Clearstead Advisors first reported a position in United Therapeutics in Q1 2025 and has held it in 6 quarters since.
Clearstead Advisors's United Therapeutics position peaked at $551K in Q4 2025.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.